LOS ANGELES–(BUSINESS WIRE)–WestPark Capital, Inc., a full-service investment bank and securities broker-dealer, today announced the closing of the follow-on offering for its client Lixte Biotechnology Holdings, Inc. 1,200,000 units consisting of one share of common stock and one warrant were sold for a total of $5,700,000 in gross proceeds. Lixte Biotechnology Holdings, Inc. began trading on The Nasdaq Capital Market (“Nasdaq”) on Wednesday, November 25, 2020 under the trading symbols “LIXT” and “LIXTW”.
WestPark Capital, Inc. acted as the book-running manager.
Lixte Biotechnology Holdings, Inc.’s registration statement relating to the offering has been filed with, and declared effective by, the United States Securities and Exchange Commission.
The offering was made pursuant to an effective registration statement on Form S-1 (No. 333-248588) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on November 19, 2020. A final prospectus describing the terms of the proposed offering was filed with the SEC and may be obtained, when available, via the SEC’s website at www.sec.gov or from: WestPark Capital, Inc. – Attention: Jason Stern, 1900 Avenue of the Stars, 3rd Floor, Los Angeles, CA 90077 or by Email: email@example.com or by telephone at (310) 203-2919.